415 Capital

415 Capital represents a specialized venture capital entity dedicated exclusively to the medical technology landscape. With headquarters in Europe and a global investment reach, the firm strategically channels resources into breakthrough innovations across cardiovascular technology, surgical robotics, digital health platforms, and advanced heart failure management solutions. Their investment philosophy centers on identifying disruptive technologies that address significant clinical needs while demonstrating clear pathways to market adoption and commercial viability.

The firm distinguishes itself through its extensive network of clinical key opinion leaders and healthcare industry veterans who provide portfolio companies with invaluable guidance on product development, regulatory strategy, and market access. This hands-on approach enables 415 Capital to offer more than just financial backing—they deliver strategic insights that help navigate the complex healthcare ecosystem and accelerate time-to-market for innovative medical solutions. Their team combines deep medical expertise with venture investment experience, creating a powerful knowledge base for evaluating technical merit and commercial potential.

The investment portfolio of 415 Capital spans both clinical-stage startups and established commercial enterprises, with particular emphasis on technologies that enhance procedural workflows and improve patient outcomes. Notable investments include companies developing next-generation cardiac monitoring devices, minimally invasive surgical platforms, and AI-powered diagnostic tools. The firm typically engages from Series A through growth stages, often participating in follow-on rounds to support portfolio companies throughout their development journey and commercial expansion phases.

Beyond capital deployment, 415 Capital actively facilitates strategic partnerships between portfolio companies and established medical device manufacturers, healthcare providers, and research institutions. This collaborative ecosystem approach has enabled numerous successful exits and strategic acquisitions within their portfolio. The firm maintains a disciplined investment thesis focused on technologies with demonstrable clinical value and reimbursement potential, ensuring that innovations not only advance medical science but also achieve sustainable commercial success in increasingly cost-conscious healthcare markets worldwide.